TY - JOUR
T1 - LFA-1/ICAM-1 ligation in human T cells promotes Th1 polarization through a GSK3b signaling-dependent notch pathway
AU - Verma, Navin K.
AU - Fazil, M. H.U.Turabe
AU - Ong, Seow Theng
AU - Chalasani, Madhavi Latha S.
AU - Low, Jian Hui
AU - Kottaiswamy, Amuthavalli
AU - Praseetha, P.
AU - Kizhakeyil, Atish
AU - Kumar, Sunil
AU - Panda, Aditya K.
AU - Freeley, Michael
AU - Smith, Sinead M.
AU - Boehm, Bernhard O.
AU - Kelleher, Dermot
N1 - Publisher Copyright:
© Copyright 2016 by The American Association of Immunologists, Inc. All rights reserved.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - In this study, we report that the integrin LFA-1 cross-linking with its ligand ICAM-1 in human PBMCs or CD4+ T cells promotes Th1 polarization by upregulating IFN-g secretion and T-bet expression. LFA-1 stimulation in PBMCs, CD4+ T cells, or the T cell line HuT78 activates the Notch pathway by nuclear translocation of cleaved Notch1 intracellular domain (NICD) and upregulation of target molecules Hey1 and Hes1. Blocking LFA-1 by a neutralizing Ab or specific inhibition of Notch1 by a g-secretase inhibitor substantially inhibits LFA-1/ICAM-1-mediated activation of Notch signaling. We further demonstrate that the Notch pathway activation is dependent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3b (GSK3b), which is mediated via Akt and ERK. Furthermore, in silico analysis in combination with coimmunoprecipitation assays show an interaction between NICD and GSK3b. Thus, there exists a molecular cross-talk between LFA-1 and Notch1 through the Akt/ERK-GSK3b signaling axis that ultimately enhances T cell differentiation toward Th1. Although clinical use of LFA-1 antagonists is limited by toxicity related to immunosuppression, these findings support the concept that Notch inhibitors could be attractive for prevention or treatment of Th1-related immunologic disorders and have implications at the level of local inflammatory responses.
AB - In this study, we report that the integrin LFA-1 cross-linking with its ligand ICAM-1 in human PBMCs or CD4+ T cells promotes Th1 polarization by upregulating IFN-g secretion and T-bet expression. LFA-1 stimulation in PBMCs, CD4+ T cells, or the T cell line HuT78 activates the Notch pathway by nuclear translocation of cleaved Notch1 intracellular domain (NICD) and upregulation of target molecules Hey1 and Hes1. Blocking LFA-1 by a neutralizing Ab or specific inhibition of Notch1 by a g-secretase inhibitor substantially inhibits LFA-1/ICAM-1-mediated activation of Notch signaling. We further demonstrate that the Notch pathway activation is dependent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3b (GSK3b), which is mediated via Akt and ERK. Furthermore, in silico analysis in combination with coimmunoprecipitation assays show an interaction between NICD and GSK3b. Thus, there exists a molecular cross-talk between LFA-1 and Notch1 through the Akt/ERK-GSK3b signaling axis that ultimately enhances T cell differentiation toward Th1. Although clinical use of LFA-1 antagonists is limited by toxicity related to immunosuppression, these findings support the concept that Notch inhibitors could be attractive for prevention or treatment of Th1-related immunologic disorders and have implications at the level of local inflammatory responses.
UR - http://www.scopus.com/inward/record.url?scp=84975292933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975292933&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1501264
DO - 10.4049/jimmunol.1501264
M3 - Article
C2 - 27206767
AN - SCOPUS:84975292933
SN - 0022-1767
VL - 197
SP - 108
EP - 118
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -